Flavin Financial Services Inc. Buys Shares of 3,269 Amgen Inc. (NASDAQ:AMGN)

Flavin Financial Services Inc. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,269 shares of the medical research company’s stock, valued at approximately $852,000.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new position in shares of Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the 3rd quarter valued at $29,000. Matrix Trust Co purchased a new position in shares of Amgen in the 3rd quarter valued at $36,000. Heck Capital Advisors LLC purchased a new position in shares of Amgen in the 4th quarter valued at $36,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of Amgen in the 3rd quarter valued at $56,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $288.87 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a 50 day moving average of $271.06 and a two-hundred day moving average of $304.11. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a market cap of $155.28 billion, a P/E ratio of 36.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is 115.24%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Piper Sandler cut their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Leerink Partners dropped their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. TD Cowen boosted their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target on the stock. Finally, Truist Financial dropped their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.